Manu Venkat was an Associate at Close Concerns from 2013 through 2015, reporting primarily on diabetes drug therapies. While at Close Concerns, he co-authored a publication examining the impact of the FDA’s policy on cardiovascular outcomes trials for diabetes drugs, based on interviews with ten experts in diabetes and cardiology. He also helped lead a survey that examined patients’ reactions to the disclosure of interim data from ongoing cardiovascular outcomes trials.
Manu graduated from Brown University in 2013 with a BS in neuroscience. He is currently a student at the University of California San Francisco School of Medicine.